20 May 2013
Keywords: bextra, trial, terminated, interim, data, survival, advantage
Article | 03 August 1999
A Phase III trial of Interneuron Pharmaceuticals and IncaraPharmaceuticals' Bextra (bucindolol HCl) in heart failure has been
terminated early by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 August 1999
4 August 1999
5 August 1999
© 2013 thepharmaletter.com